Which joint pain relief choices may help me?

What can I try before a procedure?

Easy exercise may help you keep strength and movement. You might begin below the amount that causes a lasting flare, then add slowly. A cane can also ease strain.

Heat often feels good on stiffness, while cold may soothe swelling after use. A pain cream can help a knee or hand for some people. Your doctor can say whether it’s safe for your heart, stomach, kidneys, and medicines.

Poor sleep can make soreness feel harder to bear. Gentle activity during the day may support better sleep, though the ache may still need care. You don’t have to settle everything at once.

If you’re considering a procedure, it’s fair to ask what happens and what it costs. You may also ask how long relief might last and what could go wrong. Plain answers matter.

What happens at a clinic visit?

The clinic staff will ask where the soreness began and what brings it on. They may check how far you can bend, your strength, and nearby joints. The exam comes first.

An X-ray isn’t automatic. It may be useful if the result could change your care, but old changes don’t always explain the ache. Your exam and symptoms still matter.

You’re welcome to ask what a treatment is meant to address in your joint. Cost, possible harm, likely relief, and reasons it may not suit your health are fair questions. You can compare the answers with medicine or surgery.

Some badly damaged joints still need surgery when daily tasks become too hard. Other causes need a different kind of care. A sound visit won’t force the same answer on everyone.

Sources

1. OARSI's 2019 guideline is the only major osteoarthritis guideline that grades treatments separately for people with disease in MULTIPLE joints. Its Core Treatments for polyarticular OA are arthritis education and structured land-based exercise. Critically, intra-articular corticosteroid and intra-articular hyaluronic acid were Level 1B/2 options for knee OA only and were NOT recommended for hip or polyarticular OA; oral NSAIDs were not recommended at all for people with cardiovascular comorbidity or frailty; and paracetamol/acetaminophen was conditionally not recommended.

   Bannuru RR, Osani MC, Vaysbrot EE, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. A Cochrane overview of 21 systematic reviews (381 studies, 37,143 participants) covering rheumatoid arthritis, osteoarthritis, fibromyalgia, low back pain, neck disorder and other chronic pain conditions concluded that physical activity and exercise are interventions with few adverse events that may improve pain severity and physical function - but that the quality of the evidence is low, effects on pain were inconsistent across reviews, and physical function improved significantly in 14 reviews with only small-to-moderate effect sizes. The commonest reported adverse event was increased muscle soreness that settled within weeks.

   Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH — Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews.. Cochrane Database of Systematic Reviews, 2017. DOI: 10.1002/14651858.CD011279.pub3.

3. A 2025 Bayesian network and dose-response meta-analysis of 92 randomised trials in 6,079 people with knee or hip osteoarthritis found aerobic training most likely to rank first for pain relief (SUCRA 84.7%; SMD -1.00, 95% CrI -1.50 to -0.62), ahead of strength plus flexibility (SUCRA 73.0%), yoga (63.7%), strength alone (55.9%) and flexibility alone (39.8%) - but with NO statistically significant difference between exercise types. Pooled across modalities, the dose-response relationship was U-shaped, meaning more exercise is not linearly better.

   Liang Z, Wang C, Zhang X, et al. — Optimal modality and dose of exercise for relieving pain in patients with knee or hip osteoarthritis: Bayesian pairwise, network, and dose-response meta-analyses.. Seminars in Arthritis and Rheumatism, 2025. DOI: 10.1016/j.semarthrit.2025.152855.

4. A network meta-analysis of 192 randomised trials in 102,829 patients with knee or hip osteoarthritis found that five oral preparations - diclofenac 150 mg/day, etoricoxib 60 and 90 mg/day, and rofecoxib 25 and 50 mg/day - had a 99% or greater probability of exceeding the minimal clinically important reduction in pain. Topical diclofenac (70-81 and 140-160 mg/day) had a 92.3% or greater probability. Every opioid studied had a 53% or LOWER probability of exceeding that threshold.

   da Costa BR, Pereira TV, Saadat P, et al. — Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.. BMJ, 2021. DOI: 10.1136/bmj.n2321.

5. A meta-analysis of 96 randomised trials including 26,169 participants with chronic non-cancer pain found that compared with placebo, opioids reduced pain by a weighted mean of 0.69 cm on a 10 cm visual analogue scale - well under the 1 cm minimally important difference - with a modelled 11.9% (95% CI 9.7-14.1) risk difference for achieving that minimal difference, and improved physical function by 2.04 points on a 100-point scale where the minimally important difference is 5 points.

   Busse JW, Wang L, Kamaleldin M, et al. — Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis.. JAMA, 2018. DOI: 10.1001/jama.2018.18472.

6. CDC's 2022 clinical practice guideline for prescribing opioids covers acute (under 1 month), subacute (1-3 months) and chronic (over 3 months) pain in outpatients aged 18 and over, built on GRADE. It addresses whether to initiate opioids at all, opioid selection and dosage, duration and follow-up, and assessing risk and harms - and states that people with pain should receive appropriate pain treatment with careful consideration of the benefits and risks of ALL treatment options in the context of the patient's circumstances.

   Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R — CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.. MMWR Recommendations and Reports, 2022. DOI: 10.15585/mmwr.rr7103a1.

7. A systematic review and dose-response meta-analysis of 11 randomised trials in 1,801 people with chronic musculoskeletal pain found cognitive behavioural therapy for insomnia produced a large effect on insomnia (SMD -1.34, 95% CI -2.12 to -0.56), peaking at about 450 minutes of therapy, with a large effect already at 250 minutes. The effect on pain intensity itself was not significant.

   Salazar-Mendez J, Viscay-Sanhueza N, Pinto-Vera C, et al. — Cognitive behavioral therapy for insomnia in people with chronic musculoskeletal pain. A systematic review and dose-response meta-analysis.. Sleep Medicine, 2024. DOI: 10.1016/j.sleep.2024.07.031.

8. FDA states verbatim that of the products marketed as regenerative medicine - stem cell products, stromal vascular fraction from adipose tissue, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products - 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently no FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2024.

9. A 2025 Cochrane living review of 25 randomised trials (1,341 participants) found that compared with placebo injection, stem cell injections for knee osteoarthritis MAY slightly improve pain and function up to six months, on LOW-certainty evidence: mean pain was 4.5 of 10 with placebo and 1.2 points better with stem cells; function 46.3 of 100 with placebo and 14.2 points better. Certainty was downgraded for indirectness (source, preparation and dose of cells varied across studies) and suspected publication bias - up to three larger trials were conducted and then withdrawn before reporting. Radiographic progression was not assessed in ANY included study, and the review remains uncertain about harms.

   Whittle SL, Johnston RV, McDonald S, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.